Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05378425 · ClinicalTrials.gov registry record · Phase 1
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
A Phase 1 study of Cancer and Advanced Solid Tumor, sponsored by Nectin Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 6
- Study locations
NCT05378425: Recruiting Phase 1 study of Cancer and Advanced Solid Tumor, sponsored by Nectin Therapeutics.
NCT05378425 is a Phase 1 study of Cancer and Advanced Solid Tumor that is actively recruiting participants, run by Nectin Therapeutics. The registered enrollment target is 90 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05378425, a Phase 1 study of Cancer and Advanced Solid Tumor, is actively recruiting participants, sponsored by Nectin Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a Phase 1,open-label, multi-center, first-in-human, 2-part (Part 1: dose escalation and Part 2: expansion) study, evaluating multiple doses and schedules of intravenously (IV) administered NTX-1088, with or without pembrolizumab, in patients with advanced solid malignancies (i.e., locally advanced or metastatic).
Primary Outcome
The incidence of DLTs during the DLT assessment period.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG NTX-1088
Study Locations (6)
Other
- Hadassah Medical Center - Jerusalem
- Sheba Medical Center - Ramat Gan
- Maria Skłodowska-Curie National Research Institute of Oncology - Warsaw
California
- City of Hope - Duarte
Louisiana
- Ochsner Clinic Foundation - New Orleans
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT05378425 shows while recruiting
NCT05378425 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower).
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05378425 lists 6 locations in 4 states (Other, California, Louisiana).
Frequently Asked Questions
What is clinical trial NCT05378425 about?
NCT05378425 is a clinical study titled "A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab". This is a Phase 1,open-label, multi-center, first-in-human, 2-part (Part 1: dose escalation and Part 2: expansion) study, evaluating multiple doses and schedules of intravenously (IV) administered NTX-1088, with or without pembrolizumab, in patients with advanced solid malignancies (i.e., locally ad...
What is the current status of trial NCT05378425?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2022-09-01. Estimated completion is 2026-12.
What conditions does trial NCT05378425 study?
This clinical trial studies the following conditions: Cancer, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor, Tumor, Solid.
What interventions are being tested in trial NCT05378425?
The interventions under investigation include: Pembrolizumab (DRUG), NTX-1088 (DRUG).
Who is sponsoring clinical trial NCT05378425?
This trial is sponsored by Nectin Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05378425 being conducted?
This trial has 6 study locations across California, Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05378425's enrollment target sits among peer trials
90 337th of 615 higher than 277 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI